Background: A549 carrier cells infected with oncolytic adenovirus can induce com-
granulocyte-macrophage colony-stimulating factor (GM-CSF) and was shown to improve the durable response rate in a phase III single-agent registration study. 2 This viral therapy is the first gene therapy drug approved by the US Food and Drug Administration.
An oncolytic, nonpathogenic ECHO-7 virus without genetic modification (Rigvir) was shown to significantly prolong survival in patients with early-stage melanoma without any side effects. 3 However, these viral vectors do not show a significant clinical effect with respect to improving the survival rate of patients with advanced cancers because they result in high titers of neutralizing antibodies that inhibit repetitive viral infections. 4 Adenovirus infection is highly likely to be inhibited even at initial administration because adenovirus type 5 seroprevalence is 80%-90% in humans. 5 To evade such antiadenovirus immunity, adenovirus can be coated with liposomes or polymers. However, the infectivity of these modified adenoviruses is effective only in low antibody titers, and these conditions have little antitumor effect in vivo and fail to induce complete tumor reduction. 6, 7 Furthermore, because the adenovirus may induce fatal side effects as a result of a cytokine surge, 8 it cannot be administered intravenously. However, carrier cells infected with oncolytic adenovirus can be safely administered intravenously with significant antitumor effects. 9 Many studies of replication-competent virus-infected carrier cells have been described, including PA-1 ovarian cancer cells infected with oncolytic HSV-1, 10 mesenchymal stem cells infected with oncolytic adenovirus, 11 myeloma cells infected with oncolytic measles and vaccinia viruses 12 and autologous CD8 + lymphocytes infected with oncolytic vesicular stomatitis virus. 13 However, the anti-tumor potency of these carrier cells has been insufficient because they cannot produce sufficiently high virus titers and are vulnerable to damage even before targeting cancer cells.
Human non-small cell lung cancer A549 cells have been conventionally used to produce various viruses including adenovirus because of their high virus production capacity. A previous study showed that A549 carrier cells infected with oncolytic adenovirus exhibited a significant antitumor effect in immunocompromised mice. 14 Adenoviral particle-containing cell fragments derived from these A549 carrier cells were shown to be engulfed by target cancer cells. 14 Biosafety tests for ovarian cancer-specific IAI.3B promoter-driven oncolytic adenovirus-infected A549 carrier cells for human clinical trial of recurrent solid tumors were reported in mice and rabbits. 15 However, biosafety tests for carrier cells co-infected with oncolytic adenovirus and adenovirus-GM-CSF have yet to be reported.
Midkine is overexpressed in the malignant solid tumors of humans, dogs and cats. More than one hundred million dogs and cats are bred in developed countries such as Japan, the USA and Europe, and half of animal deaths are the result of cancers. 16 Because treating cancers in companion animals by surgery, radiation and chemotherapy is impractical and uneconomical, more convenient and less invasive treatment methods should be developed. Complete treatment of tumors in companion animals by injection of carrier cells might be a potential strategy to circumvent these problems.
In the present study, to induce complete tumor reduction of intraperitoneally disseminated ovarian tumors using carrier cells infected with oncolytic adenovirus, we cloned a new carrier cell from cells that were established in our laboratory and characterized the antitumor activity and biosafety of these carrier cells. We injected the newly developed cloned carrier cells infected with midkine promoter-driven oncolytic adenovirus into mice, beagle dogs and rabbits aiming to examine antitumor efficacy and biosafety. These efficacy and biosafety tests could comprise a preliminary study for a clinical efficacy trial regarding recurrent canine and feline solid tumors and potentially provide proof-of-concept for their use as a pre-clinical efficacy trial for testing in humans.
| MATERIALS AND METHODS

| Cell lines and adenoviruses
Human ovarian cancer HEY and non-small cell lung cancer A549 cells were cultured in RPMI, and murine ovarian carcinoma OVHM cells were cultured in Dulbecco's modified Eagle's medium with high glucose. All cells were cultured with 10% heat-inactivated fetal calf serum (FCS), 5% antimycotics and antibiotics in 5% CO 2 at 37°C.
The construction and the purification of adenoviruses were performed as described previously.
14,15,17,18
| Cloning of EHMK cell lines
The EHMK cell line was established from human lung adenocarcinoma in Ehime University (Ehime, Japan) and cultured in RPMI with 10% heat-inactivated FCS, 5% antimycotics and antibiotics in 5% CO 2 at 37°C. EHMK cells were cloned by limiting dilution. EHMK cells were seeded at 0.25 cells/well in 96-well plates and incubated in 100 μl/well of RPMI medium, with another 100 μl/well of RPMI medium added into each well every 1 or 2 weeks. We selected cells that had spread from an initial single cell/well and showed stable growth.
These cells were cultured and analyzed as potential carrier cells.
| Cytotoxic assay
To evaluate the cytotoxic effects of AdE3-midkine-infected cell clones, and used for the analyses. The extraction method for each sample is shown in Table 1 . qPCR was performed using the LightCycler® Nano AdE3-midkine, Ad-cGM-CSF and Ad-fGM-CSF are shown in Table 2 . injected subcutaneously into the thigh of four beagle dogs (n = 1 for each concentration) ( Table 3) . EHMK-51-35 carrier cells were irradiated at 200 Gy, cryopreserved in liquid nitrogen and thawed before injection. Body weight, clinical symptoms and body temperature were observed every day, and saliva, feces and urine were collected every day. Blood was collected before and 1, 3, 5, 7 and 14 days after injection ( Figure 4A ). Dogs were euthanized 14 days after injection and the organs of each dog were harvested (Table 4) .
| Acute toxicity test of AdE3-midkine in beagle dogs
The experimental protocol of animal studies was approved by the Institutional Animal Care and Use Committee at Ehime University and Tokyo University of Agriculture and Technology. AdE3-midkine at 10 10 PFU was injected subcutaneously into three beagle dogs (Table 5 ). Body weight, clinical symptoms, body temperature, and saliva, urine and blood of the first beagle dog (No. 5) were observed and collected before and at 0, 3, 6, 12 and 24 h after injection ( Figure 5A ). Feces were collected before and 24 h after injection.
The dog was euthanized 24 h after injection and the organs were harvested (Table 6 ). Body weight, clinical symptoms and body temperature of the second dog (No. 6) were observed every day, and saliva, feces, urine and blood were collected before and every day after injection ( Figure 5A ). The dog was euthanized 4 days after injection and the organs were harvested (Table 6 ). Body weight, clinical symptoms and body temperature of the third dog (No. 7) were observed every day; saliva, feces, urine and blood were collected before and 0, 1, 2, 3, 4, 5, 7, 9 and 11 days after injection ( Figure 5A ). The dog was euthanized 11 days after injection and the organs were harvested 
| Statistical analysis
Data are expressed as the mean ± SD and were analyzed using an unpaired t-test, the Welch tests, one-way analysis of variance and with AdE3-midkine and Ad-mGM-CSF induced 80% or 100% of complete tumor reduction, respectively, which increased the survival rates significantly compared to A549 carrier cells (p < 0.05).
| Antitumor effect of EHMK-51-35 carrier cells on intraperitoneal tumor-bearing mice
We performed similar analyses on the antitumor effect of EHMK-51-35 carrier cells in intraperitoneal OVHM ovarian tumors in syngeneic 
| Acute toxicity test of carrier cells infected with AdE3-midkine-and ad-cGM-CSF in beagle dogs
To evaluate the acute safety of AdE3-midkine-and Ad-cGM-CSFinfected carrier cells, single doses of dose-escalated carrier cells were injected subcutaneously into four beagle dogs and the dogs were sacrificed 14 days later. Organs were removed for histological examination and qPCR of AdE3-midkine and Ad-cGM-CSF, and adenovirus bioactivity was evaluated (plaque assay) ( Figure 4B ).
Red blood cell (RBC), hematocrit (Ht), hemoglobin (HGB) and platelets decreased over 1-5 days after injection of 10 7 carrier cells ( Figure 4C ).
Mean platelet volume (MPV), platelet distribution width (PDW) and
platelet large cell ratio (P-LCR) increased during days 1-14 after injection of 10 7 carrier cells ( Figure 4D ). In the acute inflammation test, Creactive protein (CRP) and α1-acid glycoprotein (α1AG) increased over the first 7 days after injections of 10 6 and 10 7 carrier cells ( Figure 4E ).
In blood biochemistry tests, alkaline phosphatase (ALP) and lactate dehydrogenase (LDH) increased during days 3-5 after injection of Table 7 .
| qPCR and plaque assay
We constructed primer sets for each adenovirus (see Supporting information, Figure S1A ) and performed qPCR to determine specificity. AdE3-midkine was amplified by qPCR in 10 to 10 8 PFU in a dose-dependent manner with a specific melting curve (see Supporting information, Figure S1B ). qPCR of 10 8 PFU of AdE3, AdE3-midkine, Ad-cGM-CSF and Ad-fGM-CSF, using specific primers for AdE3-midkine, amplified only AdE3-midkine with a specific melting curve for AdE3-midkine (see Supporting information, Figure S1C ). Similarly, qPCR with specific primers successfully amplified AdE3, Ad-cGM-CSF and Ad-fGM-CSF with specific melting curves for each adenovirus (see Supporting information, Figure   S1D -F).
We detected 6.96 and 16.4 copies/ml of AdE3-midkine in blood samples from dogs at 1 and 3 days after injection of 10 7 carrier cells, respectively, and 26.2 and 54.3 copies/ml of AdE3-midkine in blood samples from dogs at 1 and 3 days after injection of 10 6 carrier cells, respectively, although not in other samples from the four dogs. Plaque assays showed no significant adenovirus activity in any of the samples from the dogs including blood. Ad-cGM-CSF DNA was not detected in any samples from the four dogs.
AdE3-midkine DNA and biologically active adenovirus (plaque assay) were not detected in blood, feces, urine, saliva or removed organ tissues in the three dogs injected with AdE3-midkine in the acute toxicity test.
| Acute toxicity test of AdE3-midkine in beagle dogs
To evaluate acute safety of AdE3-midkine, 10 10 PFU of AdE3-midkine was injected subcutaneously into the thighs of three beagle dogs.
Dogs were sacrificed at 24 h, 4 days or 11 days later; organs were removed for histological examination and qPCR was performed for AdE3-midkine (Table 6 ). Although no change was observed in white blood cell (WBC) levels, α1AG increased over days 2-4 after injections ( Figure 5B ). CRP started to increase 3 h after injection of AdE3-midkine, peaked on day 2 and returned to normal on day 9
( Figure 5B ). Other blood tests did not change after injections (see Supporting information, Figure S2 ). No abnormal clinical symptoms were detected in any of the three beagle dogs. A summary of abnormal clinical laboratory findings of the acute toxicity test of AdE3-midkine in beagle dogs is shown in Table 8 . AdE3-midkine were injected five times into VX2 tumors of two rabbits.
RBC, Ht and HGB decreased, and WBC, platelets, triglyceride and activated partial thromboplastin time (APTT) increased in the injected rabbits compared to controls (Figure 6 ), whereas other blood tests showed no changes (see Supporting information, Figure S3 ). Both Table 9 . Because CRP started to rise more than 3 h after injection of AdE3-midkine, whereas α1AG and WBC did not rise, we consider CRP to be a more sensitive inflammatory response marker than α1AG and WBC. In dogs and cats with inflammation, infections, trauma and malignancies, α1AG increases and is high in pyometra and parvovirus enteritis in dogs and cats and in distemper and lymphomas in dogs. However, CRP was found to be superior to α1AG
and WBC as an inflammatory reaction marker after injection of adenovirus in dogs.
Platelets decreased, whereas P-LCR, MPV and PDW increased, Because disseminated intravascular coagulation (DIC) was mild, platelets might not be consumed and increased reactively; this is consistent with our previous results obtained in a rabbit safety test in which platelets increased after low-dose injections of A549 carrier cells and decreased after high-dose injections. 15 Increased P-LCR, MPV and PDW were considered to reflect an increased platelet production response. We found that RBC, Ht and HGB did not decrease after injections of AdE3-midkine alone but decreased in a dose-dependent manner after carrier cell injections into beagle dogs and decreased in rabbits whose tumors were injected five times. APTT was extended in rabbits treated with carrier cells, probably because DIC was caused by cytolysis of the injected carrier cells. These results are also consistent with our previous safety testing results in rabbits treated with A549 carrier cells. 15 Almost no blood chemistry abnormality was 
